3StocksOnFire — US Stock Trading Community · 451+ trades · 257% returns · 15,000 members · Main Site · Trader's Guide · Articles · Video Analyses
3 Stocks On Fire
3StocksOnFire Community Forum
Home Message Boards Trader's Guide Articles Video Analysis About Us Search Register

News:

Welcome to 3StocksOnFire! US stock trading community (2005-2010) with 451+ documented trades and 15,000+ members. View Portfolios | Stock Articles | Quotes

Main Menu

VIVK.OB

Started by STOCKSEEKER, June 04, 2010, 03:20:25 PM

Previous topic - Next topic

STOCKSEEKER

I just got alerted on VIVK.  VIVK  is a biomedical/biotechnology company with transdisciplinary research that develops and acquires products in the fields of molecular medicine, electro-optics, biological handling and natural and formulary compounds that extend or improve life. Comapny came with news this morning  and looks like its setting itself up for a strong run next week. Awesome time to take a position in this one. Here is the latest news

Vivakor Announces Substantial Reduction of Company's Long Term Debt Position and Finalizes Health America Inc. Acquisition

CORALVILLE, Iowa, Jun 4, 2010 (GlobeNewswire via COMTEX) -- Vivakor, Inc. (OTCBB:VIVK) today announced the Company has reduced its long and short term debt by an additional $510,000 by converting those debts to shares of common stock. This substantial debt reduction through conversion to stock finalizes the acquisition payments for Health America Inc. and the VIVASLICES MRI software technology, which the company purchased in August of 2008. VIVASLICES is a software technology which increases image resolution of previous generations of MRI units, thereby saving hospitals and clinics with older equipment millions of dollars in costs related to purchasing new MRI units with enhanced image resolution capacity.

Vivakor Executive Chairman Matt Nicosia added this statement to the news: "This reduction of the Company's debt represents both the positive outlook by management and its creditors as we make progress on both the commercialization of VIVASLICES and other Vivakor technologies. Additionally the Company has now eliminated all of its long term debt, which increases shareholder equity and improves the balance sheet. This elimination of long term debt allows the Company to devote its resources to technology commercialization and development. We look forward to completing the Company's financing needs which will add to the Company's sustainability and improve the outlook for Vivakor."

justin76

VIVK announced the Company reduced its long and short term debt by additional $510,000 by converting those debts to shares of common stock. Solid news on this company. I really like this pick for Monday morning. @.032 great buy in!

STOCKSEEKER

VIVK, Company came with news last night. This one is having a strong day in volume. As we all know volume proceeds price. This one is going run run the rest of the week. Check out the lastest news
CORALVILLE, Iowa, June 8, 2010 (GLOBE NEWSWIRE) -- Vivakor, Inc. (OTCBB:VIVK - News) announced new markets for its VivaSight technologies and further increased revenue projections for its VivaSight division. The new market mainly includes adult vision care to be used by Ophthalmologists and Optometrists. Speaking about this new development, Matt Nicosia, Vivakor's Chairman, said, "Adult vision care is a growing market with an aging population. Existing vision screening devices do not properly detect adult issues and our technology has the capability of addressing this need. VivaSight technology is useful mainly for children's screening but has the potential to be a very valuable asset in adult vision care. Our devices use cutting edge technology developed by our multidisciplinary research model to save time and money while enhancing exactness in all our detection efforts."

Vivakor Expands Market for VivaSight Technologies to Adult Vision Care and Further Increases Revenue Outlook

Additionally, VivaSight technologies will be marketed as the best and most versatile vision screening devices on the market. Mr. Matt Nicosia stated, "The market for vision screening is not just limited to United States vision care. We have received significant attention through our commercialization partners for international use of the VivaSight technology for both private practice and government mandated vision care." This announcement will expand upon Vivakor's recently released revenue projections for its VivaSight division and increase the estimated market to $50 million annually.